Most of the exposure to misinformation about cancer treatment occurs in conversations with family and friends and on social ...

SCAN Health Plan will expand its 2026 Medicare Advantage benefits with $0 copays and higher dental, vision and allowance ...

Rhapsido is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved for chronic spontaneous urticaria (CSU).

Pfizer only offered to discount six products through the Most Favored Nation program, and healthcare policy experts suggest the real-world impact remains uncertain.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

In a recent trial, verapamil showed a trend toward preserving insulin-producing beta cells in patients with Type 1 diabetes but failed to achieve statistical significance.

Enrollment in Medicare Advantage Special Needs Plans (SNPs) has grown steadily since becoming permanent in 2018, now ...

Panelists discuss how maintaining patients on effective single therapies for Crohn’s disease is preferable to switching ...

Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for ...

In this conversation with Kristin Begley, chief commercial officer at Capital Rx, we discussed the company’s recent rebrand ...

If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 ...

As part of the Most Favored Nation pricing effort, Pfizer has agreed to invest in U.S. manufacturing and to allow access to its drugs at a discount through a new direct-to-patient website.